Earn CME with these new modules on lung cancer which include education on advances in lung cancer treatment, surgical and radiofrequency-ablative techniques, targeted therapies, and immunotherapies. Each takes less than 30 minutes to complete!

Visit IO University to access this free education now!

Target Audiences:
Clinicians practicing interventional oncology (IO) or those who are interested in learning more about IO.

Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors consists of a single lecture, with discussion, by Richard S. Finn, MD.

After viewing Hormone Receptor-Positive Advanced/Metastatic Breast Cancer, you will be better able to:
• Address the current advances and challenges of treating HR+, HER2- advanced and metastatic breast cancer
• Evaluate new safety and efficacy data of CDK4/6 inhibitors for HR+, HER2- advanced and metastatic breast cancer
• Anticipate and plan effective strategies to manage CDK4/6 inhibitor treatment-related side effects

Target Audience:
This program is intended for medical, radiation and surgery oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with breast cancer.